The global dasatinib market is gaining steady traction as demand rises for targeted therapies used in hematologic malignancies, especially chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). According to Grand View Research, the market was estimated at USD 5.59 billion in 2025 and is projected to reach USD 7.57 billion by 2033, expanding at a CAGR of 4.27% from 2026 to 2033. Growth is being supported by stronger diagnosis rates, wider acceptance of tyrosine kinase inhibitors, and the continued shift toward precision oncology. The expanding use of generic formulations is also improving affordability and access across both mature and emerging healthcare markets. Download a free sample copy of the Dasatinib Market report to understand detailed coverage and inclusions in the final report Market Segmentation By Drug Type: The generic segment led the market in 2025 with a 69.24% share, reflecting patent expirations, ...